Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Short Interest Down 80.0% in July

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 43,700 shares, a decrease of 80.0% from the June 30th total of 219,000 shares. Based on an average trading volume of 1,820,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.8% of the shares of the company are short sold.

NASDAQ:TTPH opened at $2.20 on Friday. The stock’s 50-day simple moving average is $2.47 and its 200 day simple moving average is $2.02. Tetraphase Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $8.60. The firm has a market capitalization of $15.97 million, a PE ratio of -0.12 and a beta of 2.33. The company has a quick ratio of 3.56, a current ratio of 3.66 and a debt-to-equity ratio of 0.06.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.63) by $0.32. Tetraphase Pharmaceuticals had a negative return on equity of 210.86% and a negative net margin of 798.18%. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.45 million. On average, analysts anticipate that Tetraphase Pharmaceuticals will post -3.95 EPS for the current fiscal year.

In other Tetraphase Pharmaceuticals news, major shareholder Jolla Pharmaceutical Co La purchased 3,737,360 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were acquired at an average price of $2.00 per share, for a total transaction of $7,474,720.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 5.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Sabby Management LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at about $854,000. Bank of New York Mellon Corp acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at about $36,000. BlackRock Inc. boosted its stake in shares of Tetraphase Pharmaceuticals by 20.3% during the first quarter. BlackRock Inc. now owns 69,799 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 11,757 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 52.0% during the fourth quarter. Geode Capital Management LLC now owns 30,826 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 10,541 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 38.2% during the fourth quarter. Renaissance Technologies LLC now owns 224,940 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 62,125 shares in the last quarter. 42.29% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have weighed in on the company. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Gabelli upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, G.Research cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 26th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $21.25.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Article: How can investors benefit from after-hours trading?

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.